Company Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
11.61 ^USD	-0.34%		-3.73%	+326.84%

May. 10	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	CI

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Number of employees: 11

Managers	Title	Age	Since
Punit Dhillon CEO	Chief Executive Officer	44	18-01-18
Kaitlyn Arsenault DFI	Director of Finance/CFO	-	21-10-04
Christopher G. Twitty CTO	Chief Tech/Sci/R&D Officer	52	22-12-12
Karam Takhar IRC	Investor Relations Contact	-	-
Rhea Williams LAW	General Counsel	-	21-10-06
Thomas S. Kim LAW	General Counsel	-	-
Tu Diep PRN	Corporate Officer/Principal	43	-

Members of the board	Title	Age	Since
Margaret Dalesandro BRD	Director/Board Member	77	20-08-06
Praveen Tyle BRD	Director/Board Member	64	21-07-21
Andrew Schwab BRD	Director/Board Member	53	23-08-17
Paul Grayson BRD	Director/Board Member	-	23-08-17
Punit Dhillon CEO	Chief Executive Officer	44	18-01-18
Keith Ward BRD	Director/Board Member	54	21-12-13
Deborah Charych BRD	Director/Board Member	-	23-02-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	28,067,907	26,079,747 ( 92.92 %)	0	92.92 %

Name	Equities	%	Valuation
5AM Venture Management LLC 36.27 %	10,179,505	36.27 %	131 M $
Versant Venture Management LLC 7.154 %	2,007,702	7.154 %	26 M $
Altium Capital Management LP 4.638 %	1,301,518	4.638 %	17 M $
Sphera Funds Management Ltd. 4.638 %	1,301,518	4.638 %	17 M $
GSK Equity Investments Ltd. 2.476 %	694,739	2.476 %	9 M $
Apposite Capital LLP 2.476 %	694,739	2.476 %	9 M $
Emerald Health Sciences, Inc. 2.415 %	677,633	2.415 %	9 M $
Punit Dhillon 1.415 %	397,006	1.415 %	5 M $
Paul Grayson 1.234 %	346,252	1.234 %	4 M $
Kaitlyn Arsenault 0.7474 %	209,738	0.7474 %	3 M $

Skye Bioscience, Inc.

11250 El Camino Real Suite 100

92130, San Diego

http://skyebioscience.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.61 USD

Average target price

22 USD

Spread / Average Target

+89.49%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
SKYE BIOSCIENCE, INC.	+326.84%	326M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research